Muscle-Invasive Bladder Cancer
Durvalumab regimen improves outcomes in muscle-invasive bladder cancer
Use of durvalumab before and after radical cystectomy improved outcomes for patients with muscle-invasive bladder cancer, according to results of the randomized phase 3 NIAGARA trial.
Durvalumab regimen improves survival in muscle-invasive bladder cancer
The combination of durvalumab and chemotherapy improved outcomes compared with neoadjuvant chemotherapy alone for patients with muscle-invasive bladder cancer, according to the agent’s manufacturer.
Approach predicts response to cisplatin among patients with cancer
A gene signature model appeared to predict response to cisplatin chemotherapy among tumor samples from patients with muscle-invasive bladder cancer, according to early-phase study results.
Early cessation of chemotherapy impacts survival outcomes in muscle-invasive bladder cancer
Trial represents ‘first foray’ into molecularly-guided approach to bladder sparing
A prospective phase 2 trial that evaluated risk-enabled therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer failed to meet a prespecified threshold of noninferiority, according to study results.
‘Intriguing’ data may advance more personalized approach to muscle-invasive bladder cancer
SAN FRANCISCO — Transurethral resection of bladder tumor followed by systemic therapy induced stringently defined clinical complete response among more than 40% of patients with muscle-invasive bladder cancer, according to phase 2 study results.
Enfortumab vedotin active in cisplatin-ineligible muscle-invasive bladder cancer
SAN FRANCISCO — Neoadjuvant treatment with enfortumab vedotin demonstrated promising activity among cisplatin-ineligible patients with muscle-invasive bladder cancer, according to study results presented at ASCO Genitourinary Cancers Symposium.
‘Encouraging’ results with transurethral resection, systemic therapy for bladder cancer
Transurethral resection of bladder tumor plus systemic therapy induced clinical complete response among a large subset of patients with muscle-invasive bladder cancer, according to phase 2 study results.
Screwing up cancer care
These are times when, under assault from the COVID-19 pandemic and many parts of government, those of us who are relatively powerless can seek to regain control by influencing what we can influence.
‘A call to arms’: Addressing the undertreatment of advanced bladder cancer
For decades, the 5-year survival rate for patients with advanced bladder cancer has remained at about 35%.